Navigation Links
Pathway Diagnostics Announces Commercial Availability of Second Generation SensiTrop(TM) II Molecular HIV Co-receptor Tropism Assay
Date:5/7/2008

SensiTrop II accurately classifies Dual/Mixed tropic HIV patients with

samples provided by Pfizer.

MALIBU, Calif., May 7 /PRNewswire/ -- Pathway Diagnostics announces nationwide availability of its patented second generation molecular SensiTrop(TM) II assay, combining the sensitivity of molecular heteroduplex tracking assay (HTA) technology with the specificity of molecular sequencing for determining the co-receptor tropism status of HIV infected patients. Pathway performs the SensiTrop(TM) II assay in its CLIA-certified laboratory on samples received from national reference laboratories in the U.S. and Delphic Diagnostics in Europe.

On April 28th Pathway presented data during the 2008 Clinical Virology Symposium comparing SensiTrop II with Monogram's Trofile(TM) assay. The performance of SensiTrop II was examined using 100 HIV treatment experienced patient samples provided by Pfizer and previously tested by the Trofile(TM) assay. SensiTrop II classified 41 samples as Dual/Mixed (D/M) tropic, 9 of these samples were classified as R5-tropic by Trofile. Maraviroc's phase III data stated Trofile misclassified 7-9% of patients as CCR5, similar to the results obtained in the present study.

SensiTrop II is available nationwide through national reference laboratories and is also being utilized in CCR5 compound clinical trials. "Pathway is pleased to introduce its second generation molecular HIV tropism assay nationwide, providing clinicians a fast (less than 7 days), accurate, sensitive and economical testing alternative to the currently available biological HIV tropism assay," said Walter Narajowski, Pathway Diagnostics President and CEO. "We are especially pleased with improvements in sample amplification that enable SensiTrop II to provide results from more than 95% of samples received."

SensiTrop II is the first HIV genotype co-receptor tropism test that combines the sensitivity of HTA and the specificity of DNA sequence analysis. "We are excited by the outcome of this study, and that our combined molecular approach demonstrates excellent concordance with the Trofile assay on the samples provided by Pfizer," said Terry Robins Ph.D., Vice President of Research and Development at Pathway Diagnostics.

About HIV Co-receptor tropism

The ability of the HIV virus to infect different cell types utilizing different cell surface receptors is referred to as HIV co-receptor tropism. One type of HIV that utilizes the CCR5 co-receptor has been shown to be blocked by CCR5 antagonist drugs, such as Selzentry. A different type of HIV that utilizes the CXCR4 co-receptor is not blocked by CCR5 antagonists. Therefore, determining the tropism status of HIV-infected patients has been indicated by the FDA before initiating CCR5 antagonist therapy.

About Pathway Diagnostics

Pathway Diagnostics Corporation provides biomarker development and laboratory testing services for pharmaceutical company's drug development programs. The company combines assay development expertise with a broad range of advanced technology platforms, a fully licensed CLIA laboratory, and a growing portfolio of patent-protected biomarkers for pharmaceutical companies to use in drug development and for commercial reference laboratories and in vitro diagnostic manufacturers to license for use in patient testing. Pathway effectively bridges the gap between biomarker research and biomarker commercialization, as well as ensures a regulatory-compliant environment for laboratory testing for preclinical and clinical drug development programs leading to future companion diagnostics.


'/>"/>
SOURCE Pathway Diagnostics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Study Suggests GAMMAGARD LIQUID May Target the Primary Pathway Involved in Alzheimers Disease
2. Ingenuity Systems and Pfizer Announce Strategic Partnership for Pathway Analysis
3. Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway
4. Pathway Medical Technologies Names Paul Buckman Chairman of the Board of Directors
5. Genetic pathway critical to disease, aging found
6. AspenBio Pharma Pursues FDA 510(k) Application Pathway for Appendicitis Blood Test
7. Pathway Diagnostics Announces Patent Issuance for the Diagnostic Measurement of HIV Tropism for the Initiation or Modification of HIV Therapy
8. Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
9. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
10. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
11. DxTech and Nicholas Piramal in POC Diagnostics Alliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... LONDON , May 3, 2016 ... Report Assessing Developers and Producers of Those Competitor Biologics  ... Guide to Companies, Activities and Prospects ,  ... drug companies? And what are their sales potentials? ... There you see results, trends, opportunities and revenue forecasting. ...
(Date:5/2/2016)... -- Q BioMed Inc. (QBIO), a biotechnology ... Inc. will be attending the Association for Research in ... 1-5, 2016 in Seattle Washington . ... and research partners. The meeting provides organizations the opportunity ... opportunities for the MAN-01 program for treatment of glaucoma. ...
(Date:4/29/2016)... ... 2016 , ... The MIT bioLogic design team has won multiple A' ... properties can be applied to fabric and formed into living interfaces between body and ... humidity change. The team harvested Natto cells and applied them to fabric with custom ...
(Date:4/29/2016)... ... April 29, 2016 , ... During a ... technology into a viable company, CereScan’s CEO, John Kelley, joined other Denver business ... leader and mentor in the Denver area business community, shared his top fundamental ...
Breaking Biology Technology:
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/18/2016)... --> --> Competitive Landscape Analysis ... Physical infrastructure and Perimeter Surveillance & Detection Systems ... and the continuing migration crisis in the Middle ... led visiongain to publish this unique report, which is crucial ... & security companies in the border security market and the ...
(Date:3/14/2016)... , March 14, 2016 NXTD ) ... mobile commerce market, announces the airing of a new series ... the week of March 21 st .  The commercials will ... its popular Squawk on the Street show. --> ... the growing mobile commerce market, announces the airing of a ...
Breaking Biology News(10 mins):